Development clinical

Clinical trials examine the safety and efficacy of interventions, or treatments, in human subjects. This book focuses on pharmaceutical clinical trials. The word subject is used deliberately here, since all participants in clinical trials are subjects, even if they are under the care of a personal physician, and therefore patients in that context, at the time of the trial. The key difference between clinical care and clinical research is that clinical research is conducted for the general good of the population at large, not for the specific individual benefit of the participants in the study, while clinical care is concerned with the specific well-being of each individual patient. 

It is worth noting here that a participant in a clinical trial, i.e., a subject in our nomenclature, may benefit from the drug being tested once it has been approved. At that time, the participant is now a patient and will benefit from a trial in which he or she participated. However, when actually involved in the trial, the patient was engaging in clinical research as a subject. 

Pharmaceutical and biotechnology companies often use contract research organizations (CROs) to conduct clinical trials for them. These are specialist 

Treating subjects in clinical trials in an ethical manner is of paramount importance. Several fundamental ethical principles guide drug development research in clinical trials, including  

Derenzo and Moss (2006) captured the importance of ethical considerations in all aspects of clinical studies in the following quote  

Far more complicated, and greatly more expensive, than customer and field trials of a speciality chemical is the clinical development work required for a new dmg. 

Phase I trials are the first-stage of testing in human subjects. These tests take about a year and involve about 20 to 80 normal, healthy volunteers. This phase includes trials designed to assess the safety profile, including the safe dosage range and tolerability. The studies also determine how a drug is absorbed, distributed, metabolised and excreted, and the duration of its action. 

Phase II trials are controlled studies of approximately 100 to 300 volunteer patients (people with the disease) to assess the drug s effectiveness. These trials can take about two years. 

Phase III studies are double-blind randomized controlled trials on large patient groups (1000-3000 or more) in clinics and hospitals. Physicians monitor patients closely to determine efficacy in comparison with currently available alternatives and identify adverse reactions. Phase III trials are the most expensive, time-consuming, they can take three years, and difficult trials to design and ran. 

Clearly this involves a major commitment of time and money on behalf of the company and will clearly be managed by as a project with a team and manager for the various phases. 

---

Other nootropic agents in some stage of clinical development include nebracetam (9), nefinacetam (10), and BMY 21502 (11). Nebracetam, an aminomethyl pyrrolidinone derivative, is expected to be approved in Japan in 1994 (73). In clinical studies involving patients having cerebrovascular or senile dementia of the Alzheimer s type, clinical symptoms such as spontaneous or emotional expression were enhanced in up to 71% of cases. Long-term treatment using nebracetam in patients with cerebral infarction also afforded marked improvement in most cases with few side effects (74). A review of this compound has beenpubUshed (75). 

Injected formulation of leuptoleine and triptoreline [57773-63 ] ate used to treat metastasized cancer of the prostrate, whereas an encapsulated formulation of bromocryptin [25614-03-3] is used to inhibit milk production in women after pregnancy. The performance of encapsulated hormonal polypeptides is weU documented (47). Injectable biodegradable mictocapsules loaded with fertUity control agents have been under development for a number of years and have been carried to various stages of clinical development (48) (see Contraceptives). 

Future Outlook for Antidepressants. Third-generation antidepressants are expected to combine superior efficacy and improved safety, but are unlikely to reduce the onset of therapeutic action in depressed patients (179). Many dmgs in clinical development as antidepressive agents focus on estabhshed properties such as inhibition of serotonin, dopamine, and/or noradrenaline reuptake, agonistic or antagonistic action at various serotonin receptor subtypes, presynaptic tt2-adrenoceptor antagonism, or specific monoamine—oxidase type A inhibition. Examples include buspirone (3) (only... 

Other approaches to inhibiting intramolecular cycli2ations of erythromycin have also proven successhil. Erom a series of O-alkyl derivatives of erythromycin, clarithromycin (6-0-methylerythromycin) (37) was selected for clinical development (146,147). Another approach replaced the C-8 proton of erythromycin with duorine, which was accompHshed by both chemical and bioconversion methods to yield durithromycin (38) (148). 

Pepiomycin is marketed in Japan and was in clinical trials in the United States in 1990 lihlomycin is at an early stage of development. Others include taHysomycin A [65057-90-1J, reported in 1977, which was in clinical development at one time (240), and phleomycin [11006-33-0], reported in 1956 (241), which was too toxic for dmg use. 

Future Antimycotics for Systemic Treatment. Two new antimycotics for systemic use have now reached the stage of clinical development. The first is a triazole and fluoride analogue of itraconazole. This compound (saperconazole) is extremely active 2i 2cm.%. Jisperpillus spp. and slightly more soluble. Consequentiy, intravenous adruinistration might be possible (34). The second molecule is terbinafine [91161 -71 -6] an aHylamine, C21H25N, that appears to be particularly active against dermatophytes, just like topical naftifine (35). 

The basic elements and considerations for assay development, validation, and specification assignment are reviewed briefly. Assay development produces a method that requires validation for the analysis and release of materials (bulk or formulated finished product) for use in clinical development. The cumulative analysis of materials and stability considerations is then used to established specifications for internal and regulatory submission. 

The result was of course Volume 2 and the birth of a series. The next volume, 3, was produced at the time we again felt the need to update our narrative a semidecenial period was settled upon since it seemed to represent the best compromise between currency and a sufficient body of material to merit treatment in a monograph. The volume at hand continues the series it covers the chemistry of those compounds which have been granted a United States Adopted Name (USAN) in the five years between 1983 and 1987. The bulk of the references thus fall in the 1980s the reader will note occasional much older references. We suppose that those represent compounds which were synthesized many years ago and set on the shelf at that time they were then revived for clinical development for one reason or another and a USAN applied for. 

The area of racemic switches where a single enantiomer is developed subsequently to a corresponding racemate which is already on the market has attracted much interest [7, 8]. A description of the preclinical and clinical development of dexketoprofen provides a detailed example of one of these racemic switches [21]. The regulations in Europe and the US both allow for the development of a single enantiomer from a racemate by the use of bridging studies between the old and new applications. One problem to be considered is how a company which was not responsible for the original development can provide equivalent data. 

FIGURE 9.2 Histograms showing the number of new drag entities entering phase I clinical development (blue bars), and concomitantly the number entering phase III development as a function of year. Adapted from [2]. 

Inhibition of the metabolism of extracellular adenosine or its uptake proteins is being explored for therapeutic purposes. AK inhibitors have been proposed for the treatment of pain and seizures however, the promising clinical development of these efficacious compounds was discontinued due to toxicity. 

Dtugs in clinical development that directly target the A(3 pathway are at an early stage. Inhibitors of (3- and y-secretases that can lower the A 3 production have entered clinical phase trials with (3-secretase inhibitors being years behind the development of y-secretase inhibitors. Functional y-secretase inhibitors have been shown to reduce the rate of A 3 formation in vitro and in vivo. The reduction of A 3 monomer levels could prevent oligomer formation and subsequent syn-aptotoxicity. Numerous anti-amyloid approaches to... 

A comprehensive website summarizing the status of tumor antiangiogenic compounds in various stages of clinical trial is maintained by the National Cancer Institute at www.cancer.gov/clinicaltrials/developments/ anti-angio-table. Following is a survey of the most important substances currently in clinical development. 

The growing list of endogenous inhibitors of angiogenesis holds great promise for therapeutic applications (Table 2). Substances most advanced in clinical development include Endostatin, Angiostatin, Interleukin-12, Thrombospondin, and Tumstatin. As... 

BAYK8644 is a DHP with Ca2+ channel activating properties. Although some therapeutic effects can be envisaged for such drugs (such as stimulation of glucose-dependent insulin secretion, positive inotropy), severe side effects are also predicted from animal studies (dystonic neurobehavioral syndrome, hypertension, arrhythmias), which currently prevents their clinical development. 

Several steroidal and non-steroidal glucocorticoid receptor selective dissociated agonists are in development by many pharmaceutical companies and some are now in clinical development. This suggests that the development of dissociated glucocorticoids with a greater margin of safety is possible and may even lead to the development of oral compounds that do not have significant adverse effects. 

In summary, recent years have seen the emergence of encouraging data for antibodies in clinical development that are directed against proinflammatory cytokines, inflammatory cells or co-stimulatory molecules. In particular, anti-TNFa therapies have set a new standard for symptom control and prevention of joint destruction in RA. 

The first SPRM to reach the advanced stage of clinical development for treatment of endometriosis and uterine fibroids, asoprisnil, is expected to receive FDA approval this year. The therapeutic effect of asoprisnil stems from its PR antagonist/ antiproliferative activity in the endometrium and breast. Unlike classical PR antagonists however, this compound does not induce labor in animal models of pregnancy and parturition. Recent structural studies... 

Once the initial IND application has been assigned a reference number, the sponsor can keep submitting information to the FDA file to enable the clinical development to move through the various trial phases. 

---